// App-Quantinova.ai

BSH19‐PO‐016 : Antithrombin III Replacement in patients with Acute Lymphoblastic Leukaemia undergoing L‐asparaginase based chemotherapy regimens

Researchers

Presenter

  • L. Attwell

Principal Investigators

  • R. Scott

  • J. Mainwaring

  • J. Chacko

Medical Centers

  • The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Venous thrombosis

Biomarkers

  • Breakpoint Cluster Region

  • Antithrombin III

Drug/Treatment

  • Asparaginase

  • Oncaspar

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved